High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Authors
Keywords
SARS-CoV-2, Mu, C.1.2, Pfizer BNT162b2, Moderna mRNA-1273, Ad26.COV2.S, antibodies, vaccine, COVID-19, ACE2
Journal
Cell Reports
Volume 38, Issue 2, Pages 110237
Publisher
Elsevier BV
Online
2021-12-21
DOI
10.1016/j.celrep.2021.110237
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
- (2021) Piyada Supasa et al. CELL
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2
- (2021) Donald J. Benton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
- (2021) Haolin Liu et al. CELL RESEARCH
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Structural impact on SARS-CoV-2 spike protein by D614G substitution
- (2021) Jun Zhang et al. SCIENCE
- SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
- (2021) Jun Wu et al. Nature Communications
- Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants
- (2021) Charlie Laffeber et al. JOURNAL OF MOLECULAR BIOLOGY
- In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
- (2021) Rita E. Chen et al. NATURE
- Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
- (2021) Zijun Wang et al. NATURE
- Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
- (2021) Richard A. Urbanowicz et al. Science Translational Medicine
- Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
- (2021) Takuya Tada et al. mBio
- Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand the human ACE2 receptor on binding affinity and kinetics
- (2021) Michael I Barton et al. eLife
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
- (2020) Hongjing Gu et al. SCIENCE
- SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
- (2020) Lizhou Zhang et al. Nature Communications
- An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
- (2020) Takuya Tada et al. Cell Reports
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now